Robert Langreth,
100%
The Daily's Verdict
This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.
Bias
No current examples available.
Conflicts of Interest
No current examples available.
Contradictions
No current examples available.
Deceptions
No current examples available.
Recent Articles
FDA Delays Approval of Experimental Alzheimer's Drug Donanemab, Sparking Concerns Over Safety and Efficacy
Broke On: Saturday, 09 March 2024The FDA has delayed regulatory action on donanemab, an experimental Alzheimer's drug designed to attack a sticky substance in the brain known as amyloid beta. Clinical trials have shown that it slows cognitive decline of people in the early stages of the disease. The FDA plans to hold a hearing with external advisers to explore its safety and effectiveness before making any decision on approval.